255 related articles for article (PubMed ID: 25583979)
21. Impact and Cost-Effectiveness of Hypothetical Strategies to Enhance Retention in Care within HIV Treatment Programs in East Africa.
Kessler J; Nucifora K; Li L; Uhler L; Braithwaite S
Value Health; 2015 Dec; 18(8):946-55. PubMed ID: 26686778
[TBL] [Abstract][Full Text] [Related]
22. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
Freedberg KA; Kumarasamy N; Borre ED; Ross EL; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):486-497. PubMed ID: 29620932
[TBL] [Abstract][Full Text] [Related]
23. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
Ségéral O; Limsreng S; Nouhin J; Hak C; Ngin S; De Lavaissière M; Goujard C; Taburet AM; Nerrienet E; Delfraissy JF; Ouk V; Dulioust A
AIDS Res Hum Retroviruses; 2011 Jun; 27(6):597-603. PubMed ID: 21083413
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.
Casadellà M; Manzardo C; Noguera-Julian M; Ferrer E; Domingo P; Pérez-Álvarez S; Podzamczer D; Plana M; Clotet B; Gatell JM; Miró JM; Paredes R;
AIDS; 2015 Jul; 29(12):1493-504. PubMed ID: 26244389
[TBL] [Abstract][Full Text] [Related]
25. Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya.
Culhane J; Sharma M; Wilson K; Roberts DA; Mugo C; Wamalwa D; Inwani I; Barnabas RV; Kohler PK
EClinicalMedicine; 2020 Aug; 25():100453. PubMed ID: 32954235
[TBL] [Abstract][Full Text] [Related]
26. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of genotype testing for primary resistance in Brazil.
Luz PM; Morris BL; Grinsztejn B; Freedberg KA; Veloso VG; Walensky RP; Losina E; Nakamura YM; Girouard MP; Sax PE; Struchiner CJ; Paltiel AD
J Acquir Immune Defic Syndr; 2015 Feb; 68(2):152-61. PubMed ID: 25415289
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.
Ouattara EN; Ross EL; Yazdanpanah Y; Wong AY; Robine M; Losina E; Moh R; Walensky RP; Danel C; Paltiel AD; Eholié SP; Freedberg KA; Anglaret X
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):294-302. PubMed ID: 24732870
[TBL] [Abstract][Full Text] [Related]
31. Assessing efficiency and costs of scaling up HIV treatment.
Cleary SM; McIntyre D; Boulle AM
AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
[TBL] [Abstract][Full Text] [Related]
32. Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India.
Solomon SS; Ganesh AK; Mehta SH; Yepthomi T; Balaji K; Anand S; Gallant JE; Solomon S
Indian J Med Res; 2013 Jun; 137(6):1145-53. PubMed ID: 23852295
[TBL] [Abstract][Full Text] [Related]
33. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
35. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP
Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
37. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Ahmed BS; Phelps BR; Reuben EB; Ferris RE
Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
[TBL] [Abstract][Full Text] [Related]
38. Once-daily antiretroviral therapy in a cohort of HIV-infected children and adolescents.
Jiménez-Montero B; Beceiro J; de José-Gómez MI; González-Tomé MI; Gurbindo-Gutierrez D; Martínez-Pérez J; Mellado-Peña MJ; Navarro-Gómez ML; Roa-Francia MA; Rojo-Conejo P; Saavedra-Lozano J; Jiménez de Ory S; Ramos-Amador JT;
Pediatr Infect Dis J; 2014 Oct; 33(10):1052-4. PubMed ID: 24747153
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
[TBL] [Abstract][Full Text] [Related]
40. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.
Phillips AN; Cambiano V; Miners A; Lampe FC; Rodger A; Nakagawa F; Brown A; Gill ON; De Angelis D; Elford J; Hart G; Johnson AM; Lundgren JD; Collins S; Delpech V
AIDS; 2015 Sep; 29(14):1855-62. PubMed ID: 26372391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
